PMID- 34809595
OWN - NLM
STAT- MEDLINE
DCOM- 20220221
LR  - 20221207
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 21
IP  - 1
DP  - 2021 Nov 22
TI  - Exploring the association between use of gonadotropin releasing hormones agonists 
      and prostate cancer diagnosis per se and diabetes control in men with type 2 
      diabetes mellitus: a nationwide, population-based cohort study.
PG  - 1259
LID - 10.1186/s12885-021-08941-y [doi]
LID - 1259
AB  - BACKGROUND: Gonadotropin Releasing Hormones agonists (GnRH), which are first line 
      treatment for metastatic prostate cancer (PCa), increase risk of type 2 diabetes 
      mellitus (T2DM). This study aims to quantify the association of use of GnRH with 
      diabetes control in PCa men with T2DM. METHODS: Nationwide population-based 
      cohort study in the Swedish National Diabetes Register and Prostate Cancer data 
      Base Sweden 4.1, on the association between GnRH and diabetes control in T2DM men 
      with PCa by comparing T2DM men with PCa vs. without PCa, as well as comparing 
      T2DM men with PCa on or not on GnRH. The primary exposure was use of GnRH. 
      Worsening diabetes control was the primary outcome, defined as: 1) HbA1c rose to 
      58 mmol/mol or higher; 2) HbA1c increase by 10 mmol/mol or more; 3) Start of 
      antidiabetic drugs or switch to insulin. We also combined all above definitions. 
      Cox proportional hazards regression was used to analyze the association. RESULTS: 
      There were 5714 T2DM men with PCa of whom 692 were on GnRH and 28,445 PCa-free 
      men with T2DM with similar baseline characteristics. Diabetes control was worse 
      in men with GnRH vs. PCa-free men (HR: 1.24, 95% CI: 1.13-1.34) as well as 
      compared with PCa men without GnRH (HR:1.58, 95% CI: 1.39-1.80), when we defined 
      the worsening control of diabetes by combining all definitions above. CONCLUSION: 
      Use of GnRH in T2DM men with PCa was associated with worse glycemic control. The 
      findings highlight the need to closely monitor diabetes control in men with T2DM 
      and PCa starting GnRH.
CI  - (c) 2021. The Author(s).
FAU - Lin, E
AU  - Lin E
AD  - School of Cancer and Pharmaceutical Sciences, Translational Oncology and Urology 
      Research (TOUR), King's College London, 3rd Floor Bermondsey Wing, Guy's 
      Hospital, London, SE1 9RT, UK. e.lin@kcl.ac.uk.
FAU - Garmo, Hans
AU  - Garmo H
AD  - School of Cancer and Pharmaceutical Sciences, Translational Oncology and Urology 
      Research (TOUR), King's College London, 3rd Floor Bermondsey Wing, Guy's 
      Hospital, London, SE1 9RT, UK.
FAU - Van Hemelrijck, Mieke
AU  - Van Hemelrijck M
AD  - School of Cancer and Pharmaceutical Sciences, Translational Oncology and Urology 
      Research (TOUR), King's College London, 3rd Floor Bermondsey Wing, Guy's 
      Hospital, London, SE1 9RT, UK.
FAU - Adolfsson, Jan
AU  - Adolfsson J
AD  - Department of Clinical Science, Intervention and Technology, Karolinska 
      Institute, Stockholm, Sweden.
FAU - Stattin, Par
AU  - Stattin P
AD  - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
FAU - Zethelius, Bjorn
AU  - Zethelius B
AD  - Department of Public Health/Geriatrics, Uppsala University, Uppsala, Sweden.
FAU - Crawley, Danielle
AU  - Crawley D
AD  - School of Cancer and Pharmaceutical Sciences, Translational Oncology and Urology 
      Research (TOUR), King's College London, 3rd Floor Bermondsey Wing, Guy's 
      Hospital, London, SE1 9RT, UK.
LA  - eng
PT  - Journal Article
DEP - 20211122
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 33515-09-2 (Gonadotropin-Releasing Hormone)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Cohort Studies
MH  - Databases, Factual
MH  - Diabetes Mellitus, Type 2/blood/*chemically induced/drug therapy/epidemiology
MH  - Disease Progression
MH  - Glycated Hemoglobin/analysis
MH  - Gonadotropin-Releasing Hormone/*agonists
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Insulin/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Prostatic Neoplasms/diagnosis/*drug therapy/epidemiology
MH  - Registries
MH  - Regression Analysis
MH  - Sweden/epidemiology
PMC - PMC8607667
OTO - NOTNLM
OT  - Diabetes
OT  - Gonadotropin-releasing hormone agonists
OT  - Prostate cancer diagnosis
COIS- Hans Garmo, Mieke Van Hemelrijck, Jan Adolfsson, Par Stattin and Bjorn Zethelius 
      do not have competing interests.
EDAT- 2021/11/24 06:00
MHDA- 2022/02/22 06:00
PMCR- 2021/11/22
CRDT- 2021/11/23 05:33
PHST- 2021/06/07 00:00 [received]
PHST- 2021/10/21 00:00 [accepted]
PHST- 2021/11/23 05:33 [entrez]
PHST- 2021/11/24 06:00 [pubmed]
PHST- 2022/02/22 06:00 [medline]
PHST- 2021/11/22 00:00 [pmc-release]
AID - 10.1186/s12885-021-08941-y [pii]
AID - 8941 [pii]
AID - 10.1186/s12885-021-08941-y [doi]
PST - epublish
SO  - BMC Cancer. 2021 Nov 22;21(1):1259. doi: 10.1186/s12885-021-08941-y.